Erasca Inc (ERAS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.50B
Last updated: Nov 17, 2026 at 4:41 PM ET
Erasca Inc (ERAS) Statistics
Erasca (ERAS) has a market cap of $5.50B and an enterprise value of $5.38B. Its share count is up 21.35% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 2.16% below the market cap, as cash exceeds debt.
| Market Cap | $5.50B |
|---|---|
| Enterprise Value | $5.38B |
| Latest price (Nov 17, 2026) | $13.89 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 438.37% over 52 weeks and trades 6.72% below its 50-day average.
| Beta (1Y) | 1.85 |
|---|---|
| 52-Week Change | +438.37% |
| 1-Month Change | +1.98% |
| 3-Month Change | -23.13% |
| 6-Month Change | +34.59% |
| 5-Year Change | -27.45% |
| Total Return (1Y) | +438.37% |
| Total Return (3Y CAGR) | +82.35% |
| Total Return (5Y CAGR) | -5.29% |
| Return vs SPY (1Y) | +374.11% |
| Max Drawdown (1Y) | -59.46% |
| Max Drawdown (3Y) | -67.68% |
| Sharpe Ratio (1Y) | 1.46 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $14.89 |
| 200-Day Average | $15.30 |
| 52-Week Range | $2.75 to $24.28 |
| RSI (14 Days) | 43.6 |
| Average Volume (20 Days) | 5.31M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 14.89x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 14.89x |
|---|---|
| Quick Ratio | 14.89x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -33.59% over the last 12 months, against a 5-year average of -40.36%.
| Return on Equity (ROE) | -33.59% |
|---|---|
| Return on Assets (ROA) | -30.83% |
| ROE (5Y Average) | -40.36% |
| ROA (5Y Average) | -33.38% |
| ROIC (5Y Average) | -34.29% |
Scores
ERAS has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$743.00K |
| Operating Income | -$327.65M |
| Pretax Income | -$307.94M |
| Net Income | -$307.94M |
| Reported EPS (TTM) | -$0.99 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 91.77% of the $998.94M in total assets.
| Cash and Equivalents | $118.96M |
|---|---|
| Total Debt | $0 |
| Net Cash | $118.96M |
| Net Cash Per Share | $0.35 |
| Working Capital | $611.20M |
| Shareholder Equity | $916.74M |
| Book Value Per Share | $2.66 |
| Total Assets | $998.94M |
| Total Liabilities | $82.20M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $132.00K of capital spending, operating cash flow left -$109.24M of free cash flow.
| Operating Cash Flow | -$109.11M |
|---|---|
| Capital Expenditures | $132.00K |
| Free Cash Flow | -$109.24M |
| FCF Per Share | -$0.31 |
| Depreciation and Amortization | $6.54M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
ERAS does not pay a dividend. Its free cash flow yield is -2.28%.
| FCF Yield | -2.28% |
|---|---|
| Buyback Yield | -17.51% |
| Shareholder Yield | -17.51% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ERAS
What is ERAS's market cap?
Erasca has a market cap of $5.50B. Its enterprise value, which adds debt and subtracts cash, is $5.38B.
How many shares of ERAS are outstanding?
Erasca has 344.24M shares outstanding. The count is up 21.35% from a year earlier.
Does ERAS pay a dividend?
No. Erasca does not pay a dividend.
How much debt does ERAS have?
Erasca has $0 of total debt and $118.96M of cash and equivalents, a net cash position of $118.96M.
ERAS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors